1. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial
- Author
-
Ballmann, Manfred, Hubert, Dominique, Assael, Baroukh M, Staab, Doris, Hebestreit, Alexandra, Naehrlich, Lutz, Nickolay, Tanja, Prinz, Nicole, Holl, Reinhard W, Staden, Ute, Claßen, Martin, Schuster, Antje, Mellies, Uwe, Posselt, Hans-Georg, Wiebel, Matthias, Rietschel, Ernst, Stern, Martin, Teschler, Helmut, Smaczny, Christina, Köhnlein, Thomas, Wienhausen-Wilke, Vera, Claaß, Andreas, Biedermann, Thomas, Dockter, Gerd, Köster, Holger, Hebestreit, Helge, Ballke, Ernst-Hinrich, Heuer, Hans-Eberhard, Kamin, Wolfgang, Küster, Peter, Szczepanski, Rüdiger, Keller, Klaus-Michael, Generlich, Horst, Bresser, Hans-Georg, Kopp, Matthias, Herting, Egbert, Feickert, Hans-Joachim, Hautz, Jürgen, Schilling, Birgit, Meyer, Egbert, Mall, Marcus A, Wiebicke, Wolfram, Tegtmeyer, Friedrich-Karl, Honer, Marguerite, Mosnier-Pudar, Helen, Lenoir, Gérard, Robert, Jean-Jacques, Kessler, Laurence, Weiss, Laurence, Nove-Josserand, Raphaële, Vantyghem, Marie-Christine, Munck, Anne, Wizla, Nathalie, Leroy, Sylvie, Loeuille, Guy-André, Serreau, Raphaël, Aissat, Fawzia, Thalhammer, Gabriela H, Huttegger, Isidor, Eichler, Irmgard, and Götz, Manfred
- Abstract
As survival among patients with cystic fibrosis has improved in recent decades, complications have become increasingly relevant. The most frequent complication is cystic-fibrosis-related diabetes. The recommended treatment is injected insulin, but some patients are treated with oral antidiabetic drugs to ease the treatment burden. We assessed the efficacy and safety of oral antidiabetic drugs.
- Published
- 2018
- Full Text
- View/download PDF